Skip to main content
Lobe Sciences Ltd. logo

Lobe Sciences Ltd. — Investor Relations & Filings

Ticker · LOBE CSE Manufacturing
Open in API
Filings indexed 206 across all filing types
Latest filing 2025-07-29 Capital/Financing Update
Country CA Canada
Listing CSE LOBE

About Lobe Sciences Ltd.

https://www.lobesciences.com/

Lobe Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing transformative therapies for rare and underserved diseases with unmet medical needs. The company utilizes innovative technologies, including lipid technology, to advance its pipeline. Through its subsidiary, Cynaptec Pharmaceuticals, Lobe is developing L-130 (Conjugated Psilocin™), a patented formulation engineered to provide the therapeutic effects of psilocybin without the hallucinogenic properties. Its second subsidiary, Altemia, Inc., develops S-100, a novel medical food product intended for the dietary management and treatment of Sickle Cell Disease. The company's research targets conditions such as Chronic Cluster Headache and Sickle Cell Disease.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release announcing Lobe Sciences’ engagement of ArcStone Securities as a strategic capital markets advisor. It does not present financial results, call transcripts, governance rules, or share issuance details; instead, it details a financing-related advisory engagement. This fits the definition of a Capital/Financing Update (CAP).
2025-07-29 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a private placement of common shares to raise CAD 341,425 for general corporate purposes. It details the offering terms, hold period, and use of proceeds. This constitutes a company fundraising/financing update rather than a full financial report, board change, dividend notice, or legal proceeding. It matches the 'Capital/Financing Update' category.
2025-07-29 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing the validation of a European Unitary Patent. It does not present financial results, management discussion, or detailed investor presentation materials. It is not an Annual Report, Earnings Release, or any financial filing. It does not fit any specific category such as M&A, Board changes, dividends, or share transactions. As a general corporate announcement (patent validation) that does not fit a more specific code, it falls under the fallback category: Regulatory Filings (RNS).
2025-07-08 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release announcing the completion of a spinout transaction and a US$6 million financing (non-brokered private placement) along with an option for further funding. It is neither a regulatory filing nor a financial report (e.g., no financial statements or earnings data); rather it is focused on a capital-raising and corporate restructuring event. This aligns with the “Capital/Financing Update” category (Code: CAP).
2025-06-18 English
News release - English.pdf
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new Chief Financial Officer and Executive Vice President, which is a senior management change. This fits the definition of Board/Management Information (Code: MANG). It is not a financial report, earning release, or regulatory notice but specifically an announcement of management change.
2025-06-06 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a NI 52-109Venture Issuer Basic Certificate, which is a regulatory compliance attestation by the CFO regarding interim filings (interim financial report and MD&A). It is not the interim report itself but a stand-alone certification required under Canadian securities legislation. It does not match categories like Interim / Quarterly Report (IR), Audit Report, or Management Discussion & Analysis, nor does it announce publication—it is the regulatory filing itself. Therefore the most appropriate classification is “Regulatory Filings” (RNS).
2025-04-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.